Bristol Myers Squibb Receives Positive CHMP Opinion for CAR T Cell Therapy Breyanzi for Relapsed or Refractory Follicular Lymphoma ...

Bristol Myers (BMY) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Bristol-Myers Squibb (NYSE:BMY – Free Report) had its target price boosted by Citigroup from $60.00 to $65.00 in a report published on Tuesday,Benzinga reports. They currently have a neutral rating on ...

Bristol-Myers Squibb Company (BMY) is one of the leading biopharmaceutical companies focused on developing treatments for ...

Axsome Therapeutics, Inc. , a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders, will host a virtual investor event and conference call today at ...

The Zacks Earnings ESP is a great way to find potential earnings surprises. Why investors should take advantage now.

Researchers at the Johns Hopkins Kimmel Cancer Center and Bloomberg~Kimmel Institute for Cancer Immunotherapy have developed ...

FORCIT is planning to invest more than EUR 200 million in the construction of a new TNT production facility in Pori, Finland. TNT is a widely used explosive that has been used in military applications ...

Robert F Kennedy Jr and Sen Bernie Sanders had a clash over the senator's links to Big Pharma as Trump's health nominee came ...

Merck said the Phase 3 "Hyperion" study, which was evaluating Winrevair versus placebo in recently diagnosed adults with PAH at intermediate or high risk of disease progression, had lost clinical ...

Merck (NYSE: MRK), known as MSD outside of the United States and Canada, announced today the Phase 3 HYPERION study evaluating WINREVAIR (sotatercept-csrk) versus placebo (both in combination with ...

Chief R&D and commercial officer Najat Khan, PhD, tells GEN Edge company aims to improve design of studies, accelerate enrollment, and enhance evidence generation.